Q-Check Pharmaceuticals — Care beyond Healthcare

Shifting from Traditional Risk Factors to Inflammation as Primary Therapeutic Target

For decades, the three pillars of cardiovascular risk — cholesterol, blood pressure, and smoking — have dominated clinical thinking. Emerging evidence is now establishing inflammation as a fourth, equally critical pillar, opening an entirely new therapeutic avenue for patients who remain at residual risk despite optimal conventional treatment.

High-Sensitivity CRP: A Superior Predictor?

Re-analysis of the JUPITER trial (2025) demonstrated that high-sensitivity CRP is a cardiovascular risk predictor superior to LDL-C in certain patient populations. This challenges the LDL-centric model of cardiovascular prevention and supports inflammatory biomarker screening as a routine component of risk assessment.

Colchicine: Affordable Anti-Inflammatory Cardioprotection

The LoDoCo2 trial demonstrated a 30% reduction in cardiovascular events in stable coronary artery disease (CAD) patients treated with low-dose colchicine. Following FDA approval in 2023, colchicine is now entering mainstream cardiovascular practice — at a cost of ₹50–100 per month, representing a dramatic contrast to the ₹5,000+ monthly cost of biological anti-inflammatory agents.

The Gut-Heart Axis: Microbiome and Cardiac Inflammation

Trimethylamine-N-oxide (TMAO), a bacterial metabolite produced from dietary choline and carnitine, has emerged as a measurable link between gut dysbiosis and cardiac inflammation. TMAO levels independently predict cardiovascular events — positioning gut microbiome modulation as a novel preventive strategy.

Emerging Agents

IL-6 inhibitors: Ziltivekimab is showing promise in high-risk CKD patients with elevated CRP
NLRP3 inflammasome inhibitors: Targeting the inflammasome directly in atherosclerotic plaques
Combination therapy: Statin + colchicine + GLP-1 shows synergistic anti-inflammatory benefit

Research Sources